UroGen Pharma Ltd. 3,658,537 Ordinary Shares (Par Value NIS 0.01 Per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • January 25th, 2019 • UroGen Pharma Ltd. • Pharmaceutical preparations • New York
Contract Type FiledJanuary 25th, 2019 Company Industry Jurisdiction
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • October 12th, 2018 • UroGen Pharma Ltd. • Pharmaceutical preparations • New York
Contract Type FiledOctober 12th, 2018 Company Industry Jurisdiction
UROGEN PHARMA LTD. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF __________Warrant Agreement • December 20th, 2019 • UroGen Pharma Ltd. • Pharmaceutical preparations • New York
Contract Type FiledDecember 20th, 2019 Company Industry JurisdictionTHIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between UROGEN PHARMA LTD., a company organized under the laws of the State of Israel (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
UROGEN PHARMA LTD. AND , AS WARRANT AGENT FORM OF ORDINARY SHARES WARRANT AGREEMENT DATED AS OF __________Warrant Agreement • December 20th, 2019 • UroGen Pharma Ltd. • Pharmaceutical preparations • New York
Contract Type FiledDecember 20th, 2019 Company Industry JurisdictionTHIS ORDINARY SHARES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between UROGEN PHARMA LTD., a company organized under the laws of the State of Israel (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
AMENDED AND RESTATED LOAN AGREEMENT Dated as of March 13, 2024 among UROGEN PHARMA, INC. (as Borrower, and a Credit Party), UROGEN PHARMA LTD. (as Parent, and a Credit Party), THE OTHER GUARANTORS SIGNATORY HERETO OR OTHERWISE PARTY HERETO FROM TIME...Loan Agreement • March 14th, 2024 • UroGen Pharma Ltd. • Pharmaceutical preparations • New York
Contract Type FiledMarch 14th, 2024 Company Industry Jurisdiction
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 27th, 2023 • UroGen Pharma Ltd. • Pharmaceutical preparations • New York
Contract Type FiledJuly 27th, 2023 Company Industry JurisdictionThis SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of July 26, 2023, is made by and among UROGEN PHARMA LTD., a company organized under the laws of the State of Israel (the “Company”), and the Purchasers listed on Exhibit A hereto, together with their permitted transferees (each, a “Purchaser” and collectively, the “Purchasers”).
UROGEN PHARMA LTD. ORDINARY SHARES SALES AGREEMENTSales Agreement • December 20th, 2019 • UroGen Pharma Ltd. • Pharmaceutical preparations • New York
Contract Type FiledDecember 20th, 2019 Company Industry Jurisdiction
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • October 9th, 2024 • UroGen Pharma Ltd. • Pharmaceutical preparations • New Jersey
Contract Type FiledOctober 9th, 2024 Company Industry JurisdictionThis Executive Employment Agreement (the “Agreement”), is hereby made this 7th day of October, 2024, between UroGen Pharma, Inc., a wholly owned subsidiary (the “Subsidiary”) of UroGen Pharma Ltd. (the “Parent”, and the Subsidiary and the Parent together, the “Company”), and Chris Degnan (the “Executive”) (collectively, the “Parties”).
UroGen Pharma Ltd. (the “Company”) OFFICER INDEMNITY AND EXCULPATION AGREEMENTOfficer Indemnity and Exculpation Agreement • July 13th, 2018 • UroGen Pharma Ltd. • Pharmaceutical preparations
Contract Type FiledJuly 13th, 2018 Company IndustryTHIS AGREEMENT, dated as of , 2018 is between UroGen Pharma Ltd., a company incorporated under the laws of the State of Israel (the “Company”), and , a director or officer of the Company (the “Indemnitee”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 28th, 2019 • UroGen Pharma Ltd. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 28th, 2019 Company Industry JurisdictionThis Executive Employment Agreement (the “Agreement”), is hereby made this 3rd day of January, 2019, between UroGen Pharma, Inc., a wholly owned subsidiary (the “Subsidiary”) of UroGen Pharma, Ltd. (the “Parent”, and the Subsidiary and the Parent together, the “Company”), and Elizabeth Barrett (the “Executive”) (collectively, the “Parties”).
LICENSE AGREEMENT between UroGen Pharma, Ltd. and Allergan Pharmaceuticals International Limited Dated as of October 7, 2016License Agreement • April 7th, 2017 • UroGen Pharma Ltd. • Pharmaceutical preparations
Contract Type FiledApril 7th, 2017 Company IndustryThis License Agreement (this “Agreement”) is made and entered into as of October 7, 2016 (the “Effective Date”) by and between UroGen Pharma Ltd., a corporation organized under the laws of Israel (“UroGen”) and Allergan Pharmaceuticals International Limited, a corporation organized under the laws of Ireland (“Allergan”). UroGen and Allergan are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
PRE-PAID FORWARD CONTRACTPre-Paid Forward Contract • November 6th, 2024 • UroGen Pharma Ltd. • Pharmaceutical preparations • New York
Contract Type FiledNovember 6th, 2024 Company Industry JurisdictionThis PRE-PAID FORWARD CONTRACT, dated as of March 18, 2021 (this “Agreement”), is made and entered into by and between RTW Investments ICAV, an Irish Collective Asset-management Vehicle registered in Ireland as an umbrella fund with segregated liability between sub-funds (the “Payer”), for and on behalf of its sub-fund, RTW Fund 2, and UroGen Pharma Ltd., an Israel corporation with company registration number 513537621 (the “Company”).
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • April 20th, 2016 • UroGen Pharma Ltd. • Pharmaceutical preparations
Contract Type FiledApril 20th, 2016 Company IndustryTHIS ASSET PURCHASE AGREEMENT (the “Agreement”) is made and entered into as of October 1st, 2015 (“Effective Date”), by and between TheraCoat Ltd., a limited liability company, incorporated under the laws of the State of Israel (the “Purchaser”), of the first party; and Telormedix SA, a company incorporated under the laws of Switzerland (“Seller”), of the second party (Purchaser and Seller shall be referred to as a “Party” or “Parties”, as applicable).
LICENSE AGREEMENTLicense Agreement • March 2nd, 2020 • UroGen Pharma Ltd. • Pharmaceutical preparations
Contract Type FiledMarch 2nd, 2020 Company IndustryFor the sake of clarity, notwithstanding anything to the contrary, these milestone payments are intended to be made once whether or not there is one Licensed Product or more than one Licensed Product.
October 7, 2024 Via Email and DocuSign Dong (Don) Kim don.kim@urogen.com Dear Don:Separation and Consulting Agreement • October 9th, 2024 • UroGen Pharma Ltd. • Pharmaceutical preparations
Contract Type FiledOctober 9th, 2024 Company IndustryThis letter sets forth the substance of the separation and consulting agreement (the “Agreement”) that UroGen Pharma, Inc. (the “Subsidiary”), a wholly owned subsidiary of UroGen Pharma Ltd. (the “Parent” and together with the Subsidiary, the “Company”) is offering to you to aid in your employment transition.
September 8, 2020 Peter Pfreundschuh Dear Peter:Separation Agreement • September 9th, 2020 • UroGen Pharma Ltd. • Pharmaceutical preparations
Contract Type FiledSeptember 9th, 2020 Company IndustryThis letter sets forth the substance of the separation agreement (the “Agreement”) that UroGen Pharma, Inc. (the “Company”) is offering to you to aid in your employment transition, and in accordance with the Executive Employment Agreement between the Company and you, dated July 31, 2018 (the “Employment Agreement”).
Manufacturing & Supply Agreement Between:Manufacturing & Supply Agreement • May 10th, 2022 • UroGen Pharma Ltd. • Pharmaceutical preparations
Contract Type FiledMay 10th, 2022 Company IndustryThis Manufacturing & Supply Agreement (hereinafter referred to as the “Agreement”) is made on April 24, 2020 (hereinafter referred to as the “Effective Date”) by and between:
Amendment #2 to Manufacturing and Supply AgreementManufacturing and Supply Agreement • March 14th, 2024 • UroGen Pharma Ltd. • Pharmaceutical preparations
Contract Type FiledMarch 14th, 2024 Company IndustryThis Amendment #2 to the Manufacturing & Supply Agreement (“Amendment #2”), effective as off its date of last signature (“Amendment #2 Effective Date”), is by and between UroGen Pharma Ltd., a company organized and existing under the laws of the State of Israel having an address at 9 HaTaasia St., Ra’anana 4365007, Israel (“Customer”) and Cenexi-Laboratoires Thissen S.A., a company incorporated in Belgium,having its registered office at 2-4-6, Rue de la Papyrée, B-1420 Braine-l'Alleud, also acting hereunder on behalf of its Affiliates ("Manufacturer").
LEASE EXTENSION AND MODIFICATION AGREEMENTLease Extension and Modification Agreement • August 11th, 2022 • UroGen Pharma Ltd. • Pharmaceutical preparations
Contract Type FiledAugust 11th, 2022 Company IndustryWHEREAS, Landlord and Tenant, entered into a Lease Agreement dated as of October 31, 2019 that is set to expire on January 31, 2023, and Tenant is in possession of the Demised Premises described above; and
AMENDMENT NO. 2 TO EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 13th, 2021 • UroGen Pharma Ltd. • Pharmaceutical preparations
Contract Type FiledMay 13th, 2021 Company IndustryThis Amendment No. 2 (this “Second Amendment”) to that certain Executive Employment Agreement, made as of January 23, 2020, as amended, by and between UroGen Pharma Inc., a wholly owned subsidiary (the “Subsidiary”) of UroGen Pharma Ltd. (the “Parent”) (the Subsidiary and the Parent together, the “Company”) and Mark P. Schoenberg, MD (the “Executive”). The Subsidiary, Parent and Executive are collectively referred to in this Second Amendment as the “Parties.”
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 28th, 2019 • UroGen Pharma Ltd. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 28th, 2019 Company Industry JurisdictionThis Executive Employment Agreement (the “Agreement”), is hereby made this 5th day of December, 2017, by and among UroGen Pharma, Inc., (the “Company”, a wholly-owned subsidiary of UroGen Pharma, Ltd., the “Parent”), the Parent, and Mark P. Schoenberg, MD (the “Executive”) (collectively, the “Parties”).
UROGEN PHARMA LTD. OMNIBUS AMENDMENT TO EQUITY AWARDSOmnibus Amendment to Equity Awards • May 13th, 2021 • UroGen Pharma Ltd. • Pharmaceutical preparations
Contract Type FiledMay 13th, 2021 Company IndustryThis Omnibus Amendment to those certain Stock Option Agreements and RSU Award Agreements (each as defined below) (this “Amendment”) is entered into by and between ELIZABETH BARRETT and UROGEN PHARMA LTD. (the “Company”), effective as of January 19, 2021 (“Amendment Effective Date”). Capitalized terms used but not defined herein will have the meanings given to them in the respective Equity Awards (as defined below).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 28th, 2019 • UroGen Pharma Ltd. • Pharmaceutical preparations • California
Contract Type FiledFebruary 28th, 2019 Company Industry JurisdictionThis Executive Employment Agreement (the “Agreement”), is hereby made this 17th day of January between UroGen Pharma, Inc., (the “Company”, a wholly-owned subsidiary of UroGen Pharma, Ltd., the "Parent") and Stephen L. Mullennix (the “Executive”, or “you”) (collectively, the “Parties”).
FIRST AMENDMENT TO LOAN AGREEMENTLoan Agreement • August 10th, 2023 • UroGen Pharma Ltd. • Pharmaceutical preparations • New York
Contract Type FiledAugust 10th, 2023 Company Industry JurisdictionThis FIRST AMENDMENT TO LOAN AGREEMENT (this “Amendment”), dated and effective as of June 29, 2023 (the “First Amendment Effective Date”), is made by and among UROGEN PHARMA, INC., a Delaware corporation (as “Borrower” and a Credit Party), UROGEN PHARMA LTD., a company incorporated in Israel with company registration number 513537621 (as “Parent” and a Credit Party), BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales with company number 10443190 (as the “Collateral Agent”), BPCR LIMITED PARTNERSHIP, a limited partnership established under the laws of England and Wales with registration number LP020944 (as a “Lender”), and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a “Lender”).
LICENSE and SUPPLY AGREEMENTLicense and Supply Agreement • March 14th, 2024 • UroGen Pharma Ltd. • Pharmaceutical preparations • Zürich
Contract Type FiledMarch 14th, 2024 Company Industry JurisdictionThis License and Supply Agreement (the “Agreement”) shall enter into force upon the latter date of signature of the Agreement (the “Effective Date”) by and
AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 13th, 2021 • UroGen Pharma Ltd. • Pharmaceutical preparations
Contract Type FiledMay 13th, 2021 Company IndustryThis Amendment No. 1 (this “Amendment”) to that certain Executive Employment Agreement, effective January 3, 2019, by and between Elizabeth Barrett (the “Executive”) and UroGen Pharma, Inc., a wholly owned subsidiary (the “Subsidiary”) of UroGen Pharma, Ltd. (the “Parent”) (the Subsidiary and the Parent together, the “Company”) is entered into as of this 26th day of January 2021. The Subsidiary, Parent and Executive are collectively referred to in this Amendment as “the Parties.”
March 19, 2020 Stephen Mullennix Dear Stephen:Separation Agreement • March 23rd, 2020 • UroGen Pharma Ltd. • Pharmaceutical preparations • California
Contract Type FiledMarch 23rd, 2020 Company Industry JurisdictionThis letter sets forth the substance of the separation agreement (the “Agreement”) that UroGen Pharma, Inc. (the “Company”) is offering to you to aid in your employment transition, and in accordance with the Executive Employment Agreement between the Company and you, dated October 28, 2020 (the “Employment Agreement”).
AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 13th, 2021 • UroGen Pharma Ltd. • Pharmaceutical preparations
Contract Type FiledMay 13th, 2021 Company IndustryThis Amendment No. 1 (this “Amendment”) to that certain Executive Employment Agreement, dated January 23, 2020 by and between Mark P. Schoenberg, MD (“Executive”) and UroGen Pharma, Inc. and UroGen Pharma, Ltd. (collectively, “Company”) is entered into as of this 26th day of January 2021. The Company and Executive are collectively referred to in this Amendment as “the Parties.”
AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 13th, 2021 • UroGen Pharma Ltd. • Pharmaceutical preparations
Contract Type FiledMay 13th, 2021 Company IndustryThis Amendment No. 1 (this “Amendment”) to that certain Executive Employment Agreement, dated August 12, 2020, by and between Jason Smith (“Executive”) and UroGen Pharma, Inc., a wholly owned subsidiary (the “Subsidiary”) of UroGen Pharma, Ltd. (the “Parent”) (the Subsidiary and the Parent together, the “Company”) is entered into as of this 26th day of January 2021. The Subsidiary, Parent and Executive are collectively referred to in this Amendment as “the Parties.”
ContractManufacturing and Supply Agreement • August 10th, 2023 • UroGen Pharma Ltd. • Pharmaceutical preparations
Contract Type FiledAugust 10th, 2023 Company IndustryCERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL.
SEPARATION AND RELEASE AGREEMENTSeparation and Release Agreement • February 28th, 2019 • UroGen Pharma Ltd. • Pharmaceutical preparations • Nevada
Contract Type FiledFebruary 28th, 2019 Company Industry JurisdictionThis Separation and Release Agreement (the “Agreement”) is made and entered into by and between UroGen Pharma Ltd. (“Company”) of the first part and Gary S. Titus (“Titus”) of the second part.
LEASE AGREEMENT BETWEENLease Agreement • March 2nd, 2020 • UroGen Pharma Ltd. • Pharmaceutical preparations • New Jersey
Contract Type FiledMarch 2nd, 2020 Company Industry JurisdictionThis Subordination, Non-Disturbance, Attornment and Estoppel Agreement (“Agreement”) is dated as of the __ day of __________, 20__ and is by and among ______________________, having an address at _____________________________________ (hereinafter called “Lender”); ________________________, having an office at _______________________, New Jersey _________ (hereinafter called “Tenant”); and __________________, a ________ corporation/ limited liability company having an address at _______________________, New Jersey ___________ (hereinafter called “Landlord”).
SEPARATION AND RELEASE AGREEMENTSeparation and Release Agreement • February 28th, 2019 • UroGen Pharma Ltd. • Pharmaceutical preparations
Contract Type FiledFebruary 28th, 2019 Company IndustryThis Separation and Release Agreement (the “Agreement”) is made and entered into effective as of January 3, 2019 by and between UroGen Pharma Ltd. (“Company”) of the first part and Ron Bentsur (“Bentsur”) of the second part.
INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • April 7th, 2017 • UroGen Pharma Ltd. • Pharmaceutical preparations
Contract Type FiledApril 7th, 2017 Company IndustryTHIS INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is made as of September 18, 2014, by and among TheraCoat Ltd., a private company incorporated under the laws of the State of Israel of, 13 HaSadna St., P.O. Box 2397, Ra’anana 4365007, Israel (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.”
UROGEN PHARMA LTD. AMENDMENT NO. 1 TO SALES AGREEMENTSales Agreement • November 9th, 2020 • UroGen Pharma Ltd. • Pharmaceutical preparations • New York
Contract Type FiledNovember 9th, 2020 Company Industry JurisdictionReference is made to the Sales Agreement, dated as of December 20, 2019 (the “Sales Agreement”), between Cowen and Company, LLC (“Cowen”) and UroGen Pharma Ltd., a company organized under the laws of the State of Israel (the “Company”). All capitalized terms used in this Amendment No. 1 to the Sales Agreement between the Company and Cowen (this “Amendment”) and not otherwise defined herein shall have the respective meanings assigned to such terms in the Sales Agreement. Cowen and the Company hereby agree as follows: